Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2025
Date Filed: April 7, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a procedural filing to incorporate a specific notice by reference into existing registration statements (Forms S-8 and F-3) rather than a financial results announcement.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this document. The filing references the submission of Exhibit 99.1, a "Notice Under Section 708A," but does not detail the content of that notice within the text provided.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the formal incorporation of the referenced notice into the company's registration statements.
Investor Verification Checklist
- Verify the content of the "Notice Under Section 708A" (Exhibit 99.1) referenced in this filing, as the text itself does not summarize it.
- Confirm the status of the referenced Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
- Review the company's most recent Form 20-F or quarterly reports for actual financial performance data, as this 6-K contains none.